No results for ‘’
Dr Lal Pathlabs Ltd
NSE: LALPATHLAB BSE: 539524
â‚ą1905.20
(1.41%)
Mon, 10 Aug 2026, 08:02 pm
Market Cap (in Cr)31976.9
PE Ratio58.81
Dividend0.84
Health Services
Medical/Nursing Services
24.5KDr Lal Pathlabs Analysis
dividend
- Dividends paid are well covered by earnings (2.3x coverage).
- Dividends after 3 years are expected to be well covered by earnings (3.9x coverage).
- Dividend payments have increased, but Dr. Lal PathLabs only paid a dividend in the past 4 years.
- Whilst dividend payments have been stable, Dr. Lal PathLabs has been paying a dividend for less than 10 years.
- Dr. Lal PathLabs's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dr. Lal PathLabs's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Dr. Lal PathLabs's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Dr. Lal PathLabs's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- Dr. Lal PathLabs is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Healthcare industry average.
- An improvement in Dr. Lal PathLabs's performance (ROE) is expected over the next 3 years.
- Dr. Lal PathLabs's revenue growth is expected to exceed the India market average.
- Cash flow for Dr. Lal PathLabs is expected to increase but not above the 50% threshold in 2 years time.
- Dr. Lal PathLabs's earnings are expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
- Dr. Lal PathLabs's earnings growth is positive but not above the India market average.
- Dr. Lal PathLabs's earnings are expected to decrease over the next year.
- Dr. Lal PathLabs's net income is expected to increase but not above the 50% threshold in 2 years time.
- Dr. Lal PathLabs's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Dr. Lal PathLabs's revenue is expected to grow by 11.7% yearly, however this is not considered high growth (20% yearly).
health
- Dr. Lal PathLabs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Dr. Lal PathLabs is profitable, therefore cash runway is not a concern.
- Dr. Lal PathLabs is profitable, therefore cash runway is not a concern.
- Dr. Lal PathLabs has no debt, it does not need to be covered by operating cash flow.
- Dr. Lal PathLabs has no debt, it does not need to be covered by short term assets.
- Dr. Lal PathLabs's cash and other short term assets cover its long term commitments.
- Dr. Lal PathLabs currently has no debt however we can't compare to 5 years ago as we have no data for that period.
- Dr. Lal PathLabs has no debt, therefore coverage of interest payments is not a concern.
- Dr. Lal PathLabs has no debt.
- High level of physical assets or inventory.
management
- The tenure for the Dr. Lal PathLabs board of directors is about average.
- Dr. Lal PathLabs individual insiders have only sold shares in the past 3 months.
- The average tenure for the Dr. Lal PathLabs management team is less than 2 years, this suggests a new team.
past
- Dr. Lal PathLabs's year on year earnings growth rate has been positive over the past 5 years.
- Dr. Lal PathLabs used its assets more efficiently than the IN Healthcare industry average last year based on Return on Assets.
- Dr. Lal PathLabs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Dr. Lal PathLabs's 1-year earnings growth is less than its 5-year average (13.4% vs 14.3%)
- Dr. Lal PathLabs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Dr. Lal PathLabs's earnings growth has not exceeded the IN Healthcare industry average in the past year (13.4% vs 14.4%).
value
- 539524 outperformed the Healthcare industry which returned 9.1% over the past year.
- 539524 outperformed the Market in India which returned -14.5% over the past year.
- Dr. Lal PathLabs's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Dr. Lal PathLabs's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Dr. Lal PathLabs is overvalued based on assets compared to the IN Healthcare industry average.
- Dr. Lal PathLabs is poor value based on expected growth next year.
- Dr. Lal PathLabs is overvalued based on earnings compared to the IN Healthcare industry average.
- Dr. Lal PathLabs is overvalued based on earnings compared to the India market.
- BSE:539524 is flat (-0.3%) underperforming the Healthcare industry which returned 5.4% over the past month.
- BSE:539524 is flat (-0.3%) underperforming the market in India which returned 8% over the past month.